AzarGen is a biotechnology company focused on developing – PRODUCTS - recombinant human surfactant protein-B (targeting respiratory disease associated with surfactant dysfunction) and a plant-made CD20-binding monoclonal antibody for B-cell depletion therapy (targeting autoimmune diseases) using advanced genetic engineering and synthetic biology techniques in plants. AzarGen has developed proprietary synthetic DNA promoters - SYNTHETIC BIOLOGY PLATFORM - enabling enhanced expression in genetically engineered plants for biomanufacturing applications in biopharmaceuticals, biomaterials, cellular agriculture and biofuels. AzarGen is the owner of two PATENT families relating to the company's respiratory therapeutic candidate and synthetic promoter technology. The AzarGen management team has extensive experience in plant biotechnology, genetic engineering, synthetic biology and human genetics. The team is supported by an experienced advisory board for strategic guidance and intellectual property management. Based in Stellenbosch, South Africa, AzarGen is supported by South Africa’s Industrial Development Corporation (IDC). Further information is available at www.azargen.com.